Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (475)	11/27/2000 3:06:50 PM
From: juneau_boy	Read Replies (1) \| Respond to of 3559

Hang on, here we go---- Regeneron to Announce Obesity Phase II Clinical Trial Results Tomorrow Conference Call and Live Webcast at 10 a.m. EST TARRYTOWN, N.Y.--(BUSINESS WIRE)--Nov. 27, 2000--Regeneron Pharmaceuticals Inc. (Nasdaq:REGN - news) will issue a press release tomorrow morning, Nov. 28, 2000, announcing the results of a Phase II clinical trial to study the safety and efficacy of AXOKINE® in inducing weight loss in severely obese patients. Regeneron will also hold a conference call tomorrow morning, beginning at 10 a.m. EST, to discuss the trial results. The conference call will be broadcast live on the Internet at www.regeneron.com and at www.themeetingson.com (click on Web Conferencing, then scroll down to Webcast and click on ``If you have a reservation number, access Webcast now''). The reservation number for the Webcast is 17049541. The Webcast will be available at both sites for 14 days. An audio replay of the conference call will be available for 48 hours, beginning approximately at noon on Nov. 28, 2000 and ending at noon on Nov. 30, 2000. To access the replay of the call, dial 800/633-8284 and enter the eight-digit reservation number 17049541. International callers should dial 858/812-6440 and enter the eight-digit reservation number 17049541. Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer, will be discussing Regeneron's business and the AXOKINE Phase II trial results at the Robertson Stephens Medical Conference at 10:30 a.m. EST on Nov. 29, 2000 at The Pierre in New York City. Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron's platform technologies include Targeted Genomics(tm), Functionomics(tm) and Designer Protein Therapeutics(tm). Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, and severe constipating conditions. Additional information about Regeneron and recent news releases are available on Regeneron's Web site at www.regeneron.com. Fax copies of news releases can be obtained from Regeneron's News-on-Demand Service by dialing 800/311-0841